The mRNA-based Pfizer vaccine has demonstrated remarkable efficacy and is approved for use across a wide range of age groups from children aged 12 and up to the elderly.
Members of the Moderna COVID-19 mRNA vaccine study group recently released a short correspondence in the New England Journal of Medicine, highlighting the persistent antibody response after the first six months of receiving the second dose of this vaccine.
By Marija Djekic Ivankovic Due to the ongoing pace of the COVID-19 pandemic, alongside the available vaccines, there is increased interest in complementary therapeutics. Several anti-SARS-CoV-2 antibody-based therapies have been approved for emergency-use, but viral resistance represents a major challenge in light of emerging variants. According to a recent study published in Nature, a [...]
Long-term data have emerged regarding the durability of antibody responses in people who had COVID-19. In a recent Nature article, a team lead by Rockefeller University researcher Dr. Michel Nussenzweig reported immunity results from 63 people recovering from severe COVID-19 (convalescent individuals) up to 12 months post-infection.
Multiple sclerosis (MS) is an autoimmune disorder that is often treated with drugs that deplete B cells and therefore interfere in the process of antibody production.
Many respiratory viral infections, such as the seasonal flu, target the two most immune-vulnerable populations, younger children and seniors.
Antibody levels stay elevated throughout six months after the second dose of the Moderna COVID-19 vaccine
The Moderna mRNA-1273 vaccine was previously shown to be 94.1% efficacious at preventing COVID-19 illness in a phase 3 trial of 30,420 volunteers.
Interim analysis suggests the Oxford-AstraZeneca vaccine is not effective against the South African variant
A randomized control trial in South Africa, the results of which have been published in the New England Journal of Medicine, has found that the Oxford-AstraZeneca vaccine, although safe, is not effective against the B.1.351 variant, also known as the South African variant.
Quantifying antibodies made in response to SARS-CoV-2 vaccination: comparable outcomes from five commercial assays
The evaluation of antibodies against SARS-CoV-2 is critical to the management of the COVID-19 pandemic.
SpaceX does not just send red convertibles into space, they are also now a cohort for SARS-CoV-2 immunity.